Dope Co., Ltd. (CEO Shin Yong-woo), a company specializing in bio-tissue transplant materials, announced on the 2nd that it had been selected as a ‘Global IP Star Company’ hosted by the Korean Intellectual Property Office and the Korea Invention Promotion Association.
'Global IP Star Company' is a national R&D support program that provides intensive support for securing overseas intellectual property rights (IP) and establishing IP strategies for small and medium-sized enterprises with export performance or high export potential for three years. This year, strong small and medium-sized enterprises with advanced technology and solid IP portfolios were finally selected after fierce competition, and through this, Dop received external recognition for its technology and IP competitiveness.
Dope is a biomaterials company that has independently developed 'E-CELL®', a decellularized human tissue manufacturing technology based on supercritical carbon dioxide (CO₂) fluid. E-CELL® technology is a next-generation biotissue processing technology that overcomes the limitations of existing chemical processes and effectively removes cells while preserving ECM (extracellular matrix), growth factors, and tissue structure, and can be applied to various tissues such as skin, bone, cartilage, and nerves.
In particular, it is evaluated as a technology that fits the ESG (Environment, Society, Governance) era because it is based on carbon dioxide that is environmentally friendly and harmless to the human body. From the early stage of technology development, Dope has focused on technology design that takes environmental and economic feasibility into account, and the E-CELL® brand that reflects this is based on three keywords: 'Extracting Cell', 'Eco-friendly', and 'Economic'. Through this technology, Dope is presenting a new global standard in the decellularization field.
With this selection as a global IP star company, Dope will receive various government support such as strengthening its overseas patent portfolio, developing brands and designs, and establishing IP risk response strategies, and will accelerate its entry into the global market. In addition, as the company aims to be listed under the Technology Special Act this fall based on the originality and commerciality of E-CELL®, it is expected to be an opportunity for Dope to externally verify its technological prowess.
A Dope official said, “E-CELL® is a brand that embodies not only excellent technology but also an ESG management philosophy that puts people and the environment first,” adding, “With the selection as a global IP star company as momentum, we will further strengthen our IP strategy and expand our competitiveness in the global market. We will also take a leap forward as a company through listing.”
- See more related articles
You must be logged in to post a comment.